ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension in single-use vials is available in 300-mg or 400-mg strength vials. The 300-mg kit includes (NDC ): 300-mg, single-use vial of ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension lyophilized powder
After the first ABILIFY MAINTENA injection, administer oral aripiprazole (10 mg to 20 compared ABILIFY MAINTENA 400 mg or 300 mg to placebo in patients with.
Of the 2,649 patients exposed to ABILIFY MAINTENA, 1,316 patients have received at least 9 ABILIFY MAINTENA 400 mg/300 mg injections, (i.e
aripiprazole. ABILIFY MAINTENA 300 mg. ABILIFY MAINTENA 400 mg. Powder and solvent for prolonged-release suspension for injection. Re-evaluation. Adopted by the
ABILIFY MAINTENA, , OTSUKA PHARMACEUTICAL CO LTD, ARIPIPRAZOLE 300 MG / SYR. Previous1Next ABILIFY MAINTENA. ARIPIPRAZOLE 300 MG / VIAL. ABILIFY
Présentations du médicament ABILIFY MAINTENA. ABILIFY MAINTENA 300 mg : préparation pour suspension injectable à libération prolongée ; 1
ARIPIPRAZOLE long-acting injection (Abilify Maintena). Pre-treatment: (see 200 mg. CYP3A4 inducers. Avoid use. Patients taking 300 mg of Abilify Maintena.
injections of 400 mg Abilify Maintena at separate injection Two injection start: The starting dose should be 2 separate injections of 300 mg Abilify Maintena
Aripiprazole for prolonged release injectable suspension (Abilify Maintena), 300 mg or 400 mg, IM injection in the treatment of schizophrenia.
Comments